Previous Article | Next Article 
Mol Cell Biol, May 1998, p. 2997-3009, Vol. 18, No. 5
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
AP-1 Factors Play an Important Role in
Transformation Induced by the v-rel Oncogene
Jarmila
Kralova,1,2
Andrew S.
Liss,1
William
Bargmann,1 and
Henry R.
Bose Jr.1,*
Department of Microbiology and the Institute
for Cellular and Molecular Biology, University of Texas at Austin,
Texas 78712-1095,1 and
Institute of
Molecular Genetics, Czech Academy of Sciences, 166 37 Prague 6, Czech Republic2
Received 23 June 1997/Returned for modification 11 August
1997/Accepted 29 January 1998
 |
ABSTRACT |
v-rel is the oncogenic member of the Rel/NF-
B family
of transcription factors. The mechanism by which v-Rel induces
transformation of avian lymphoid cells and fibroblasts is not precisely
known. However, most models propose that v-rel disrupts the
normal transcriptional regulatory network. In this study we evaluated
the role of AP-1 family members in v-Rel-mediated transformation. The
overexpression of v-Rel, c-Rel, and c-Rel
resulted in a prolonged
elevation of c-fos and c-jun expression and in
a sustained repression of fra-2 at both the mRNA and
protein levels in fibroblasts and lymphoid cells. Moreover, the
transforming abilities of these Rel proteins correlated with their
ability to alter the expression of these AP-1 factors. v-Rel exhibited
the most pronounced effect, whereas c-Rel, with poor transforming
ability, elicited only moderate changes in AP-1 levels. Furthermore,
c-Rel
, which exhibits enhanced transforming potential relative to
c-Rel, induced intermediate changes in AP-1 expression. To directly
evaluate the role of AP-1 family members in the v-Rel transformation
process, a supjun-1 transdominant mutant was used. The
supjun-1 mutant functions as a general inhibitor of AP-1
activity by inhibiting AP-1-mediated transactivation and by reducing
AP-1 DNA-binding activity. Coinfection or sequential infection of
fibroblasts or lymphoid cells with viruses carrying rel
oncogenes and supjun-1 resulted in a reduction of the
transformation efficiency of the Rel proteins. The expression of
supjun-1 inhibited the ability of v-Rel transformed
lymphoid cells and fibroblasts to form colonies in soft agar by over
70%. Furthermore, the expression of supjun-1 strongly
interfered with the ability of v-Rel to morphologically transform avian
fibroblasts. This is the first report showing that v-Rel might execute
its oncogenic potential through modulating the activity of early
response genes.
 |
INTRODUCTION |
The v-rel oncogene of the
avian reticuloendotheliosis virus (REV-T) encodes a member of the
Rel/NF-
B family of transcription factors (reviewed in references
11, 26, and 27). REV-T induces a
rapidly fatal lymphoma in young chickens and transforms both immature
hematopoietic cells and fibroblasts in culture (7, 9, 21, 32, 48,
52, 56). The product of the v-rel oncogene,
p59v-rel (v-Rel), is a nuclear phosphoprotein
that is a truncated and mutated version of the avian proto-oncoprotein
c-Rel (69, 78). The deletion of the C terminus of c-Rel to
produce v-Rel resulted in the removal of a cytoplasmic retention
sequence and transactivation sequences (29, 62). Like other
members of the Rel/NF-
B family, c-Rel and v-Rel have a conserved N
terminus, the Rel homology region. This region contains sequences
important for DNA binding, homo- and heterodimerization, and nuclear
localization (5, 24, 29, 45). Both v-Rel and c-Rel form
homodimers and heterodimers with other family members and bind to
B
sites located in the promoter and enhancer elements of various effector
genes (42). DNA-binding complex formation and
transactivation activity are necessary for the full transforming
potential of v-Rel (20, 32, 50, 58, 64). Due to the deletion
of sequences involved in transcriptional activation however, v-Rel
exhibits a lower transcriptional activity than does c-Rel (5, 40,
54, 62).
The regulation of Rel/NF-
B family members is mediated, in part, by
their interaction with I
B proteins. I
B proteins sequester these
transcription factors in the cytoplasm and inhibit their DNA binding
(reviewed in references 6, 8, and
28). In response to external stimuli that result in
the activation of Rel/NF-
B complexes, I
B-
is proteolytically
degraded, allowing the nuclear translocation of these transcription
complexes (35, 44, 72). The gene encoding I
B-
is then
upregulated by the nuclear Rel/NF-
B factors, establishing an
autoregulatory loop that results in a transient response to exogenous
stimuli (17, 18, 41, 51). We have previously shown that
v-Rel activates the transcription of I
B-
far less efficiently
than c-Rel and the induction of I
B-
occurs with delayed kinetics
(38, 65). Moreover, avian I
B-
transcription is
synergistically regulated by Rel and AP-1 factors (49).
v-Rel, however, is less effective in the synergistic stimulation of the
I
B-
promoter than is c-Rel. Because v-Rel is impaired in the
induction of I
B-
, the activity of v-Rel is less sensitive to
autoregulation by I
B-
. This is likely to be an important feature
in the establishment of transformation by v-Rel. The functional
interaction between AP-1 factors and Rel suggested by the I
B-
promoter analysis led us to define whether AP-1 factors play a role in
the v-Rel transformation process. While this work was in progress, Fuji
et al. demonstrated that the c-jun promoter is activated by
v-Rel, providing additional evidence that c-Jun expression may be
involved in the v-Rel transformation pathway (22).
Functional AP-1 activity is required for cellular transformation by
certain oncogenes (v-src, v-yes,
v-fps, c-Ha-ras, and N-terminally truncated
c-raf) but is not essential for transformation induced by
others (v-ros, v-myc) (70). AP-1 is a
dimeric transcription factor composed of proteins belonging to two
different families of proto-oncogene products, Jun (c-Jun, JunB, and
JunD) and Fos (c-Fos, FosB, Fra-1, and Fra-2) (reviewed in references
4 and 31). AP-1 binds to a
specific DNA target sequence, TGA(C/G)TCA, known as the TPA response
element, to increase the transcriptional activities of target genes
(3). fos and jun are immediate-early response genes (47). This family of genes is highly,
rapidly, and transiently activated upon stimulation of quiescent cells by external stimuli, leading to cell proliferation. Moreover, the
altered expression of several individual Fos or Jun proteins can result
in the transformation of cells in culture, either alone or in
cooperation with other activated oncogene products (14, 55,
60). The AP-1 transcription system is subject to complex regulation (4). Therefore, analysis of the individual
activities of different members of the AP-1 family in v-Rel-transformed
cells is required to understand the general mechanism by which v-Rel may affect AP-1 activity. To test the potential role of AP-1 in v-Rel
transformation, the expression of the known chicken AP-1 components
(c-jun, c-fos, fra-2, and
junD) was analyzed at the mRNA and protein levels. In this
study, we demonstrate that c-jun, c-fos, and
fra-2 are differentially expressed in v-Rel-transformed cells compared with control cells, while the expression of
junD is unaffected. Moreover, the transforming ability of
oncogenic Rel proteins (v-Rel, c-Rel
, and c-Rel) correlates with
their ability to alter the expression of c-Jun and other AP-1 factors. These observations suggest an involvement of AP-1 factors in the Rel-induced transformation pathway. To provide direct evidence for a
functional role for AP-1 factors in v-Rel transformation, we have used
the targeted inhibition of AP-1 activity by a supjun-1 transdominant mutant. The supJun mutant is missing a
transactivation domain but retains both dimer-forming and DNA-binding
activities (70). The simultaneous or sequential introduction
of the supjun-1 transdominant mutant with v-rel
or c-rel
in fibroblasts and lymphoid cells had a
significant inhibitory effect on the transformation potential of these
oncogenes.
 |
MATERIALS AND METHODS |
Cells and growth conditions.
Chicken embryo fibroblast (CEF)
cultures were prepared from 10- to 11-day-old embryos (SPAFAS, Norwich,
Conn.) and were routinely grown in Dulbecco's modified Eagle's medium
(JRH Biosciences) supplemented with 5% fetal calf serum (Summit
Biotechnology), 3% chicken serum (GIBCO-BRL), and antibiotics as
previously described (48). For serum starvation, cultures of
5 × 106 cells/100-mm plate were grown for 18 h
in Dulbecco's modified Eagle's medium supplemented with 0.2% calf
serum. Subsequently, these cells were stimulated by the addition of
10% calf serum for the times indicated. DT95 cells, an avian B-cell
line derived from a chicken infected with avian leukosis virus, and the
v-rel-transformed lymphoid cell line 160/2 (T-cell line)
were maintained as previously described (37). C4-1 cells
(RECC-UTC4-1), a non-virus-producing lymphoblastoid pre-B-cell line
obtained from reticuloendotheliosis virus transformation of spleen
cells (52, 81), were grown under the same conditions as the
other lymphoid cell lines.
Plasmid constructs and virus production.
All recombinant
techniques were carried out by conventional procedures (63).
Oligomer TNFE2 (obtained from J. Palma) containing five AP-1 consensus
binding sites (TGACTCA) was cloned into the BglII
site of the pGL2-promoter vector (Promega, Madison, Wis.) to create the
construct (AP-1)5SV40-luc. The other reporter constructs used in transactivation experiments include
73/+63coll CAT and
60/+63coll CAT, which contain the collagenase promoter with or without the AP-1-binding site, respectively (both kindly provided by P. Vogt) (1). The transdominant mutant supjun-1, as
well as v-rel, c-fos, and c-jun, was
cloned into the expression vector pRc/RSV (Invitrogen) for
transient-transactivation studies. supjun-1 was excised from
the pDS3 vector (kindly provided by H. Iba) with BglII,
blunt ended, and ligated with a blunt-ended XbaI-digested vector, pRc/RSV. Similarly, a 1.6-kb XbaI-ClaI
fragment of v-rel with previously described modifications
and a 1.3-kb KpnI fragment of c-fos (obtained
from R. Muller) were blunt ended and ligated as described for
supjun-1 (57). The c-jun construct was
provided by P. Vogt.
To deliver the v-rel and c-rel
oncogenes or
the supjun-1 transdominant mutant into cells to obtain
stable cell lines, we used a replication-competent retrovirus vector,
composed of pREP and pDS3 SalI fragments containing the 5'
and 3' halves of the provirus, respectively (61). The
supjun-1 expression vector was generated by insertion of a
5'-end-truncated human c-jun sequence into the
BglII site of pDS3 prior to ligation with the pREP
SalI fragment (70). The v-rel
expression vector was constructed by insertion of the 1.6-kb
XbaI-ClaI fragment, which was filled in with
Klenow and ligated with the blunt-ended, BglII-cut pDS3. The
C-terminal deletion construct of c-Rel (c-Rel
) was generated as
described previously, and a EcoRV-EagI fragment
was blunted and cloned into a blunt-ended BglII site of pDS3
as described for v-rel (48).
For the production of recombinant viruses, sup
jun-1,
v-
rel, and c-
rel
in the pDS3 vector were
completely digested with
SalI
and ligated to the
SalI-digested pREP-A or pREP-B to create the
replication-competent viruses (
70). Ligated DNAs (4 µg)
were
transfected into CEF cultures by a calcium phosphate precipitate
technique, and replication-competent virus stocks were collected
from
the cultures 6 or 7 days after transfection, aliquoted, and
kept frozen
at

70°C (
16). The infectious titer of virus stocks
was
measured in CEF cultures by an in situ expression assay as
described
below.
In situ immunohistochemical detection of virus-infected
cells.
To determine the infectious unit titer (IU) of the
collected virus stocks, in situ immunohistochemical detection was used for virus-infected cells with an antibody against gag viral proteins. CEF cultures to be tested for viral infection were plated (7 × 105 cells/60-mm petri dish) 24 h before infection. The
following day, the growth medium was replaced with 0.5 ml of medium
containing various dilutions of the viral stock. After a 2-h
incubation, the medium was removed and cells were overlaid with 0.7%
agar medium and grown to full confluency for an additional 5 days. The
agar was removed, and the cells were washed with phosphate-buffered saline (PBS) and fixed in 2% paraformaldehyde in PBS for 30 min. The
fixed cells were permeabilized by incubation in acetone-methanol (1:1)
for 2 min. Subsequently, the cells were treated with the primary
antibody, i.e., polyclonal rabbit anti-p27gag
serum (Life Sciences, St. Petersburg, Fla.) diluted 1:500 in PBS with
2% bovine serum albumin (BSA) for 1 h at room temperature. After
being washed in PBS, the cells were incubated under the same conditions
with an alkaline phosphatase-conjugated goat anti-rabbit serum
(Kirkegaard & Perry Laboratories, Gaithersburg, Md.) for 1 h. The
alkaline phosphatase activity was detected in the presence of 1 mg of
Fast Red TR (Sigma) per ml and 0.2 mg of Napthol AS-MX phosphate
(Sigma) per ml in 0.1 M Tris (pH 8.2)-0.1 M NaCl. The reaction was
stopped after 10 to 20 min by extensive washing in PBS, and
macroscopically visible red-stained infectious centers were counted.
Virus infections.
Fresh CEF cultures (plated at 7 × 105 cells/60-mm dish) were infected with retroviruses by
incubating the virus for 2 h with the cells in the presence of
Polybrene (Sigma) at 8 µg/ml. The incubation was then continued
overnight after dilution of Polybrene to 2 µg/ml with medium. The
medium was replaced the next day, and cells were subcultured as
necessary. Usually after two passages, cells exhibited morphological
transformation following infection with retroviruses containing
v-rel.
To obtain cell populations of doubly infected CEF cultures expressing
both v-Rel and the supJun mutant at similar levels,
two sets of vectors
that differ with respect to envelope subgroup
specificity (A and B)
were used for each gene. CEF cultures were
first infected with the
virus from subgroup A first and, 4 days
later, superinfected with the
virus from subgroup B to deliver
the second gene (
70).
Alternatively, doubly infected cultures
were obtained through the
application of both types of viruses
simultaneously (coinfection). We
routinely infect CEF cultures
at a multiplicity of infection of 2. For
superinfection of lymphoid
cell lines with sup
jun-1, a
multiplicity of infection of 5 to
10 was used.
DNA transfections and reporter assays.
Secondary cultures of
CEFs were seeded at a density of 7 × 105 cells per
60-mm-diameter dish 1 day before transfection. DNA was transfected into
CEF cultures by calcium phosphate precipitation techniques as
previously described (49). Briefly, 0.1 µg of chloramphenicol acetyltransferase (CAT) reporter DNA (
73/+63coll CAT,
60/+63coll CAT) was cotransfected with 3 µg of vector DNA (pRc/RSV;
Invitrogen) or vectors containing the c-jun or
supjun-1 genes (3 and 8 µg, respectively). The total DNA
concentration was kept constant by adding an unrelated plasmid DNA
(pBluescript). At 24 h after the glycerol shock, the cells were
harvested (34). CAT activity in cell extracts containing
equal amounts of protein was determined with the CAT enzyme-linked
immunosorbent assay kit (Boehringer Mannheim Corp. no. 1363727) as
specified by the manufacturer. The absorbance of the samples was
measured at 410 nm with a microtiter plate enzyme-linked immunosorbent
assay reader (Dynatech no. MR5000). The same procedure with several
modifications was applied to deliver luciferase constructs. A 1-µg
portion of luciferase construct [(AP-1)5SV40-luc] was
cotransfected with vectors expressing c-jun,
c-fos, v-rel, c-rel, and
supjun-1 as indicated. At 36 h posttransfection, the
cells were harvested (65). Luciferase activity for equal
amounts of protein was determined by the luciferase assay system
(Promega no. E4030) with an MLX microtiter plate luminometer
(Dynatech).
In vitro transcription and translation.
Template plasmids
containing c-jun, c-fos, or supjun-1
in the pTZ18R vector, cloned in the sense orientation with the T7
promoter, were linearized by restriction enzymes which cut the
polylinker 3' of the inserted gene. For in vitro protein synthesis, the
TNT T7 quick coupled transcription/translation system (Promega no. L1170) was used as specified by the manufacturer. To determine the size
and quantity of the in vitro-translated proteins, parallel reactions
were done in the presence of [35S]methionine. These in
vitro-translated proteins were analyzed by electrophoresis through
sodium dodecyl sulfate (SDS)-10% polyacrylamide gels and visualized
by autoradiography.
EMSA analysis.
Nuclear extracts for gel shift analysis were
prepared as described previously (65, 66). For the
electrophoretic mobility shift assay (EMSA) reactions, 5 µg of
nuclear extracts was incubated for 15 min at room temperature in a
total reaction volume of 25 µl containing 20 mM Tris (pH 7.5), 75 mM
KCl, 40 µM EDTA, 5% glycerol, 1 mM dithiothreitol, 100 µg of BSA
per ml, and 1 µg of poly(dI-dC). Then 0.2 ng of double-stranded AP-1
oligonucleotide (end labeled with 32P) (Santa Cruz
Biotechnology, Inc. no. sc-2501) was added to the reaction mixture. The
mixture was then incubated for an additional 20 min at room
temperature. For competition analysis, a 100-fold molar excess of
unlabeled oligonucleotide was added. For supershift analysis, 2 µl of
the appropriate antiserum was added, and the mixture was incubated on
ice for 45 min before the addition of the labeled oligonucleotide.
Samples were then analyzed by electrophoresis in a 5% polyacrylamide
gel with 0.25× Tris-borate-EDTA. Following the electrophoresis, the
gels were dried and DNA-protein complexes were visualized by
autoradiography.
In vitro-translated proteins were mixed proportionally according to the
efficiency of the in vitro translations (total volume,
4.5 µl) and
incubated at 37°C for 45 min to allow protein-protein
association.
Then 5 µl of binding buffer (10 mM HEPES [pH 7.9],
50 mM NaCl, 4 mM
MgCl
2, 0.1 mM EDTA, 4 mM spermidine, 2 mM dithiothreitol,
100 µg of BSA per ml, 15 µg of salmon sperm DNA per ml, 15%
glycerol)
and 1 µg of poly(dI-dC) (Pharmacia) were added, and the
mixture
was incubated for a further 15 min at room temperature. Then 1
ng of
32P-labeled, double-stranded DNA probe containing the
FSE2-AP-1
sequence was added, and the incubation was continued at
4°C for
15 min (
71). The samples were loaded on a 5%
polyacrylamide
gel and electrophoresed at 4°C for an extended period
to provide
maximum separation of complexes. This extended
electrophoresis
resulted in the free probe being electrophoresed from
the gel.
The oligonucleotides used for EMSA are listed below. Bold letters
represent the 12-
O-tetradecanoylphorbol-13-acetate
responsive
element, while underlined letters indicate the nucleotides
that
are different between the AP-1 and AP-1m
oligonucleotides. AP-1
5'-CGCTTGA
TGACTCAGCCGGAA 3'
3'-GCGAACT
ACTGAGTCGGCCTT
5' AP-1m
5'-CGCTTGA
TGACTTGGCCGGAA-3'
3'-GCGAACT
ACTGAACCGGCCTT-5'
FSE2
5'-TCGACTATTAAAAACA
TGACTCAGAGGAAAAC-3'
3'-GATAATTTTTGT
ACTGAGTCTCCTTTTGAGCT-5'
Protein analysis.
Antibodies used for protein detection
include a polyclonal antiserum made against a bacterially expressed
c-Jun (USC30-4), kindly provided by P. Vogt. A c-Jun/AP-1
affinity-purified polyclonal antiserum corresponding to a highly
conserved DNA-binding domain (residues 247 to 263) of mouse c-Jun was
purchased from Santa Cruz Biotechnology (no. cs-44X). Since this
antiserum is broadly cross-reactive with Jun proteins of chicken,
mouse, and human origin, it was used to detect the human supJun mutant.
To detect chicken Fra-2 protein, we used anti-Fra-2 (Q-20) serum, which is cross-reactive with avian Fra-2 (Santa Cruz Biotechnology no. sc-604X). This antiserum was raised against a peptide corresponding to
amino acids 3 to 22 mapping at the N terminus of Fra-2 of human origin
(this peptide sequence differs from the corresponding chicken sequence
by two amino acids). Two v-Rel-specific antipeptide antisera were
generated against the 13 C-terminal residues from the env sequences (anti-E1) or the 10 N-terminal env residues
(anti-R5). c-Rel specific antiserum (anti-A5) was raised against
C-terminal residues 531 to 541.
Cell lysates of virus infected cells were prepared as previously
described (
53). A 20-µg portion of total cellular protein
or lysate derived from 2 × 10
5 cells was then
resolved by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) followed
by electrophoretic transfer to nitrocellulose
membrane (Optitran
BA-S83; Schleicher & Schuell, Keene, N.H.)
(
80). For
detection of supJun protein, 50 µg of nuclear extract
was subjected
to SDS-PAGE on a discontinuous 4, 10, and 18% step
polyacrylamide gel
(0.75 mm thick) by using a Hoefer minislab
electrophoretic unit with
0.1 M Tris-0.1 M Tricine-0.1% SDS as
the cathode buffer and 0.2 M
Tris (pH 8.9) as the anode buffer.
Immunoblots were treated with 5%
nonfat dried milk and then incubated
with specific antisera (polyclonal
rabbit antisera diluted 1:1,000
in 5% nonfat dried milk). The
secondary antibody was goat anti-rabbit
serum conjugated with
horseradish peroxidase (Jackson Immunoresearch
Lab., Inc. West Grove,
Pa, no. 111-035-003) used at a 1:5,000
dilution in 5% nonfat dried
milk. The protein bands were visualized
by the enhanced
chemiluminescence Western blotting detection system
(Dupont NEN). The
results were quantified by densitometric analysis.
For
35S metabolic labeling, cells were incubated for 3 h in methionine- and cysteine-free medium containing 5% fetal calf
serum
for exponentially growing cells and 0.2% fetal calf serum for
starved cells. The cells were then labeled with 500 µCi of
[
35S]methionine-[
35S]cysteine label mix
(NEG-072 express protein labeling mix [NEN
Life Science Products])
per ml for 1 h. For growth stimulation,
serum-starved cells
(starved for 21 h) were exposed to 10% calf
serum, which was
added to the culture simultaneously with the
label mix. Subsequently,
the cells were harvested and nuclear
extracts were prepared from
labeled cells by the same method as
that used for gel shifts. Proteins
in nuclear extracts were subjected
to a first immunoprecipitation with
the Fra-2 antiserum, and supernatant
fluids from these precipitations
were reprecipitated with an anti-c-Jun
antiserum.
Northern blot analysis.
Total cellular RNAs were prepared
from cells by acidic guanidinium thiocyanate-phenol-chloroform
extraction (19). For Northern blot analysis, RNA (15 or 20 µg) was separated on 1% agarose-formaldehyde gels (63).
This was followed by capillary transfer to nylon filters (Hybond-N+),
which were then stained with methylene blue to confirm equal loading
and RNA transfer. The filters were hybridized at 65°C in the presence
of 10% dextran sulfate, 5× SSPE (0.9 M NaCl, 0.05 M sodium phosphate,
5 mM EDTA), 5× Denhardt's solution (0.1% BSA, 0.1% Ficoll, 0.1%
polyvinylpyrrolidone), 0.5% SDS, and 50 µg of salmon sperm DNA per
ml with one of the following randomly primed cDNA probes: 1-kb
XbaI fragment of chicken c-jun, 1.3-kb
KpnI fragment containing a full-length cDNA of
c-fos, 1.46-kb EcoRI-PstI fragment of
chicken junD, or 0.26-kb
PvuII-HindIII fragment of chicken
fra-2 (23, 33, 59, 60, 70). As a control for RNA
loading, the filters were rehybridized with a 1.2-kb EcoRI
fragment of human glyceraldehyde phosphate dehydrogenase (GAPDH). The
results were quantified by densitometric analyses.
Soft agar colony formation.
CEF cultures (105
cells) sequentially infected or coinfected with two species of viruses
were seeded in soft agar (0.37%) on top of a bed of hard agar (0.75%)
4 days after infection as previously described (48). The
cells were refed with additional soft agar medium at weekly intervals.
The plates were scored for the development of colonies 4 weeks after
seeding. Lymphoid cells, C4-1 or 160/2, were superinfected with
supjun-1 virus or DS3 virus (carrying no insert) and were
seeded into 0.37% soft agar 10 days after infection (104
cells/60-mm plate). Colonies were counted 2 weeks after seeding, and
the mean value from three plates was determined.
 |
RESULTS |
AP-1 factors are differentially expressed in Rel-transformed
cells.
We have previously observed that the steady-state level of
c-Jun in v-rel-transformed fibroblasts is elevated relative
to that in nontransformed cells, suggesting that early-response genes may play a role in the v-rel-induced transformation process.
To test this hypothesis, we have analyzed the effect of
v-rel expression on c-jun as well as the other
known members of the AP-1 family. CEF cultures were infected with
retrovirus expression vectors containing no insert (DS3),
v-rel, c-rel
, or the c-rel
proto-oncogene. v-rel is a strongly transforming oncogene,
c-rel is a poorly transforming proto-oncogene, and
c-rel
, whose product lacks the 40 C-terminal amino acids
of c-Rel, exhibits intermediate transforming activity (48).
Ten days after infection, the time when cells exhibit the morphological
change associated with the transformed phenotype, cell extracts were
prepared, RNA was isolated, and the expression of various AP-1 factors
(c-jun, c-fos, fra-2, and
junD) was analyzed by Northern analysis.
As shown in Fig.
1A, the c-
jun
mRNA level was elevated twofold in v-
rel as well as in
c-
rel
-transformed CEF cultures. A twofold
increase in the
c-
jun mRNA level was also observed in the
v-
rel-overexpressing
lymphoid cell line DT95, whereas
c-
rel overexpression in these
cells resulted in only a
slight increase (1.3-fold) in the level
of c-
jun transcripts
(Fig.
1C). In contrast to c-
jun,
junD mRNA
levels
were the same in control and transformed cells (Fig.
1A).
Since
c-
fos mRNA is not usually detected in exponentially growing
CEF cultures, total RNA was also extracted from serum-starved
and
serum-stimulated cells. As shown in Fig.
1B, c-
fos mRNA
(lanes
7 to 9) was highly expressed in the control cells (lane 7) as
well as in the
rel-transformed cells (lanes 8 and 9) after
serum
stimulation but was undetectable in serum-starved cells (lanes
4 to 6). However, in exponentially growing v-Rel-transformed cells,
the
level of c-
fos mRNA was increased (4.6-fold) compared to
that
in the vector-infected control cells (lanes 1 and 3), whereas
in
c-Rel

-expressing cells, only a slight increase (1.6-fold)
was
observed (lane 2). To determine if the elevation of the level
of
c-
fos mRNA in v-Rel-transformed cells is a transient or a
prolonged
feature, RNA was harvested at different time points after
v-
rel infection and the levels were evaluated by Northern
analysis (Fig.
1D). Two days after infection, as soon as v-Rel was
expressed
in infected CEF cultures (data not shown), the
c-
fos mRNA level
was increased (twofold) and remained high
(four- to fivefold increase)
relative to control cells at the later
time points examined. The
upregulation of c-
fos mRNA was
much more pronounced in v-Rel-transformed
cells than in
c-Rel

-transformed cells (Fig.
1B, lanes 2 and 3;
Fig.
1C, lanes C
and T). Surprisingly, Rel overexpression seems
to have a suppressive
effect on the mRNA levels of another member
of the
fos
family,
fra-2. In both cell types examined, i.e., CEFs
(Fig.
1B) and the lymphoid cell line DT95 (Fig.
1C), a lower level
of
fra-2 was detected following infection with
rel
expressing
viruses in exponentially growing cells (Fig.
1B, lanes 2 and
3;
Fig.
1C, lanes C and T). For v-Rel- and c-Rel

-transformed CEF
cultures, about a 2.5-fold reduction compared to control cells
was
observed, whereas in DT95 cells, a more pronounced suppression
following v-Rel overexpression (4.5-fold decrease) was detected.
Furthermore, the lower level of expression of the
fra-2 mRNA
was
also maintained in Rel-transformed cells after growth stimulation
compared to the expression in control cells (DS3) (Fig.
1B, compare
lane 7 with lanes 8 and 9). While the
fra-2 mRNA was highly
stimulated
by serum in control cells (lanes 4 and 7), the same growth
stimulus
resulted in lower induction and overall expression of the
fra-2 mRNA in v-Rel-transformed cells (compare lanes 6 and
9). In conclusion,
Rel overexpression seems to have a differential
effect on the
mRNA levels of the various members of the AP-1 family: it
upregulates
c-
jun and c-
fos, downregulates
fra-2, and does not appear to influence
the expression of
junD.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 1.
Expression levels of mRNAs encoding AP-1 components in
Rel-overexpressing cells. (A) Expression of c-jun and
junD mRNA in CEF cultures infected with viruses carrying no
insert (DS) or the oncogene c-rel (C ) or
v-rel (V). A 15-µg sample of each RNA was used for
Northern blot hybridization, first with radiolabeled c-jun
cDNA and then with a human GAPDH probe to demonstrate the RNA loading
(left two panels). For junD mRNA analysis, 20 µg of total
RNA was used and the membrane was hybridized with junD cDNA
followed by rehybridization with GAPDH (right two panels). (B) Serum
stimulation of c-fos and fra-2 mRNA. Three
different cell pools of DS3-, c-rel -, and
v-rel-infected CEF cultures were grown in serum
(exponentially growing cells [E]), or were serum starved for 18 h in the presence of 0.2% calf serum (quiescent cells
[G0]) and then stimulated by the addition of 10% calf
serum for 90 min prior to RNA extraction (serum-stimulated cells
[G1]). Total RNA (20 µg) isolated from these various
cultures was sequentially analyzed by Northern blot hybridization with
radiolabeled chicken c-fos, fra-2, and human
GAPDH DNA probes. (C) Expression levels of endogenous c-jun
and fra-2 mRNA in infected DT95 lymphoid cells. DT95 cells
were infected with REV-C (C) or REV-T (T) in the presence of the CSV
helper virus. Three weeks after infection, the expression of these
oncoproteins was confirmed by Western blot analysis (see Fig. 2B) and
total RNA (20 µg) was subjected to Northern blot analyses with
c-jun and fra-2 DNA probes as described above.
(D) Time course of c-fos mRNA induction in CEF cultures
following infection with a retrovirus expressing v-rel.
Total RNA (20 µg per lane) was extracted at the time points (days)
indicated and sequentially analyzed by Northern blot hybridization with
radiolabeled c-fos and then GAPDH probes.
|
|
Next, we analyzed the effect of v-Rel on AP-1 expression at the protein
level. The steady-state expression of endogenous c-Jun
in exponentially
growing CEF cultures infected with different
viruses was analyzed by
Western immunoblotting. After blotting,
the membranes were cut into two
parts. The upper portion was incubated
with v-Rel- or c-Rel-specific
antiserum to evaluate the expression
of the virus-delivered oncogenes
v-
rel or c-
rel and c-
rel
,
respectively.
The lower portion was incubated with anti-c-Jun antiserum
to detect
endogenous c-Jun. As shown in Fig.
2A, v-
rel-infected CEF
cultures
expressed 4-fold more c-Jun and c-
rel
-infected
CEF cultures expressed
3.5-fold more c-Jun than did control DS3 cells.
In DT95 lymphoid
cells infected with REV-T (carrying the
v-
rel oncogene) or REV-C
(carrying full-length
c-
rel) in the presence of the chicken syncytial
virus (CSV)
helper virus, a similar 3.7-fold or 2-fold increase,
respectively, was
observed (Fig.
2B). These results consistently
demonstrated that in
both cell types examined, there is a correlation
between the
transformation potential of v-
rel, c-
rel, or
c-
rel
and the expression pattern of c-
jun.
Generally, the strongly transforming
oncoprotein v-Rel had the most
pronounced effect on c-Jun expression,
while full-length c-Rel had only
a moderate effect. c-Rel

, which
exhibits enhanced transforming
ability compared to c-Rel, also
has a stronger effect on c-Jun levels
than did c-Rel (
48). Unfortunately,
we were not able to make
the comparison for JunD, because JunD
expression was undetectable with
the available antisera (data
not shown).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 2.
Expression of endogenous c-Jun, Fra-2, and c-Fos in
cells overexpressing Rel proteins. (A) Proteins in whole-cell lysates
from control and c-rel - or v-rel-expressing
CEF cultures (each analysis contained the equivalent of 2 × 105 cells) were resolved on SDS-10% polyacrylamide gel
and then subjected to immunoblotting with the enhanced
chemiluminescence Western blotting detection system. Membranes were cut
into two parts; the upper portion was incubated with anti-v-Rel ( v-Rel) serum to detect p59v-rel or anti-c-Rel
serum ( c-Rel) to detect p64c-rel , and the
lower portion was incubated with anti-c-Jun ( c-Jun) antiserum to
detect c-Jun (40 kDa). The expression of these proteins was monitored
at 10 days postinfection. (B) Proteins in whole-cell lysates
corresponding to 2 × 105 cells per lane from DT95
infected with REV-T (v-rel) or REV-C (c-rel) in
the presence of the CSV helper virus were analyzed by Western blot
analysis as described above for CEF cultures. (C) Exponentially growing
(E) and serum-stimulated (G1) CEF cultures (expressing
v-rel [V] or DS3 [DS]) were 35S labeled for
60 min, and proteins in nuclear extracts were immunoprecipitated with
anti-Fra-2 serum (lanes 1 to 4). Then the supernatant fluids from these
Fra-2 precipitations were subjected to a second precipitation with
anti-c-Jun serum (lanes 5 to 8) to detect coprecipitated c-Fos.
Proteins in immunoprecipitates were resolved by SDS-PAGE (10%
polyacrylamide) and visualized by autoradiography after exposure of the
X-ray film for 3 weeks.
|
|
Due to the low level of Fra-2 and c-Fos expression,
radioimmunoprecipitations were performed to detect changes in the
expression
of these proteins. Control and v-Rel-transformed cells which
were
grown under normal growth conditions

exponentially growing cells
(E) or serum-starved cells stimulated with 10% calf serum
(G
1)
were labeled with
[
35S]Met-[
35S]Cys, and nuclear extracts
were prepared. Proteins in these extracts
were immunoprecipitated with
Fra-2 antiserum (Fig.
2C, lanes 1
to 4), and the supernatant fluids
from these Fra-2 precipitations
were subjected to a second
precipitation with c-Jun antiserum
to detect associated c-Fos (lanes 5 to 8). By using this approach,
it was demonstrated that Fra-2 proteins
(the molecular masses
of unphosphorylated and phosphorylated forms
range from 40 to
46 kDa) were expressed at a higher level in control
cells than
in v-
rel-infected cells and that this pattern of
expression did
not change substantially after serum stimulation (lanes
1 to 4).
c-Fos proteins were detected by secondary
coimmunoprecipitations
with anti-c-Jun antiserum. In serum-stimulated
CEF cultures (infected
with DS3 or v-
rel), highly
phosphorylated c-Fos was observed at
the expected molecular mass,
whereas in exponentially growing
cells, c-Fos was barely detected.
These protein analyses correlated
well with the mRNA analysis which
shows that the Fra-2 was less
abundant in v-Rel-transformed cells and
that the level was not
dramatically increased by serum stimulation
compared to that in
control cells. For the detection of c-Fos, we
relied on coimmunoprecipitation
of c-Fos with c-Jun (chicken c-Fos
antiserum was not available).
These results might not reflect the
actual quantitative level
of c-Fos in the examined cells. This may
explain why the elevated
expression of c-Fos was not detected in
exponentially growing
v-Rel-transformed cells as was observed at the
mRNA level.
In conclusion, the altered mRNA and protein expression patterns of
various AP-1 members in Rel-transformed cells compared
to those in
control cells led us to examine the role of AP-1 in
the Rel-induced
transformation pathway.
Expression of a supjun-1 transdominant mutant
downregulates c-jun.
We used the targeted inhibition of AP-1
by a supjun-1 transdominant mutant to define a functional
role for AP-1 factors in v-Rel transformation. Since c-jun
expression is positively regulated by its own product (2),
the presence of supJun is likely to downregulate c-jun
expression. To test this hypothesis, the expression of endogenous
c-jun in supjun-1-expressing CEF cultures versus control cells (DS3 infected) was assayed by Northern and Western blot
analyses. Figure 3A shows that in
supjun-1-expressing CEF cultures, the c-jun mRNA
level was decreased twofold. Similarly, the expression of the supJun
protein reduced the steady-state level of the c-Jun protein
approximately twofold as determined by densitometry (Fig. 3B). The
membrane was stained with Ponceau S to verify equal protein loading,
and then the top half of this Western blot was incubated with c-Jun
antiserum to detect endogenous c-Jun (40 kDa) and the bottom half was
incubated with a panspecific Jun antiserum to detect the human supJun
protein. The multiple proteins detected in the bottom panel most
probably represent breakdown products of supJun (expected size, 15 kDa). In addition, a 1.5-fold decrease in the expression of endogenous
c-Jun was detected in the REV-T-transformed lymphoid cell lines C4-1
and 160/2 superinfected with the virus expressing supjun-1
(Fig. 3C). These results indicate that one of the inhibitory effects of
supjun-1 on AP-1 activity may be the direct downregulation
of c-jun.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of supjun-1 expression on the level of
endogenous c-jun. (A) Level of the c-jun
transcript in CEF cultures infected with DS3 and supjun-1
viruses (top panel). CEF cultures were harvested 10 days after
infection, and total RNA was extracted and subjected to Northern blot
analyses (20 µg per lane) with a radiolabeled c-jun cDNA
probe. RNA loading was demonstrated by showing 28S rRNA (bottom panel).
(B) Nuclear extracts (50 µg) from infected CEF cultures were analyzed
on a discontinuous 4, 10, and 18% step polyacrylamide gel as described
in Materials and Methods and then subjected to immunoblotting. After
blotting, the membranes were cut into two parts. The top half was
incubated with anti-c-Jun serum to detect endogenous c-Jun (40 kDa),
and the bottom half was incubated with a panspecific Jun antiserum to
detect the human supJun protein. (C) Nuclear extracts (50 µg) from
v-Rel-transformed lymphoid cells C4-1 and 160/2 were isolated, and
protein expression was analyzed 10 days after superinfection with
DS3 or supjun-1 viruses as described for panel B.
|
|
SupJun inhibits c-Jun as well as v-Rel-induced
transactivation.
SupJun, which is missing the transactivation
domain of c-Jun but retains its specific DNA binding activity and
leucine zipper domain, is expected to be a transdominant inhibitor of
AP-1-mediated transcriptional regulation (70). To
demonstrate that supJun inhibits AP-1-mediated transactivation, we have
used a reporter construct from the human collagenase promoter
(containing a single AP-1-responsive element) linked to the CAT gene
(
73/+63coll CAT). This reporter was cotransfected with expression
plasmids (Rc/RSV; Invitrogen) carrying c-jun,
supjun-1, or both. Figure 4A,
lane 2, demonstrated a 3.5-fold increase over basal-level endogenous activity in CAT when c-jun was transfected into CEF
cultures. This activity was mediated by AP-1, since a reporter CAT
construct with the AP-1 site deleted (
60/+63coll CAT) showed no
increase in CAT activity when cotransfected with c-jun (lane
8). Moreover, cotransfection with increasing amounts of
supjun-1 with a constant amount of c-jun resulted
in suppression of CAT activity (lanes 5 and 6). In addition,
supjun-1 was able to suppress the basal level of endogenous
AP-1 activity (lanes 3 and 4).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 4.
(A) Inhibition of c-Jun-induced transactivation of
collagenase promoter by supjun-1. Transactivation was
assessed by measuring CAT activity in extracts of CEF cultures
cotransfected with or without supjun-1 and the 73/+63coll
CAT reporter gene (lanes 1 to 6, solid bars) or 60/+63coll CAT with
the AP-1 site deleted (lanes 7 and 8, open bars) 24 h
posttransfection (34). (B) Inhibition of v-Rel-induced
transactivation by supjun-1. CEF cultures were cotransfected
with expression vectors for the genes indicated, along with a
luciferase reporter construct with or without multiple AP-1 binding
sites cloned in front of the SV40 promoter, respectively (lanes 1 to 7, solid bars; lanes 8 to 12, open bars). Luciferase activity for equal
amounts of protein was determined as described in Materials and Methods
36 h after transfection (65). The fold activation was
determined by dividing the actual chloramphenicol or luciferase
activity obtained in the presence of c-Jun, c-Fos, v-Rel, and supJun
expression vectors by the activity of the reporter when the cells were
cotransfected with an "empty" expression vector, pRc/RSV (defined
as baseline activity 1.0). The mean results from three to five
experiments are shown. Standard errors were determined; however, in
some cases they are not visible in the given activation scale for the
luciferase assays.
|
|
It has been shown recently that v-
rel can transactivate the
c-
jun promoter (
22). Based on this observation,
one might expect
that v-
rel, by activating c-
jun,
could also potentially modulate
the collagenase reporter construct. We
were, however, unable to
show that v-
rel can mediate the
transactivation of the CAT-linked
collagenase reporter construct (data
not shown). However, using
a luciferase construct with multiple
AP-1-binding sites cloned
upstream of the simian virus 40 (SV40)
promoter [(AP-1)
5SV40-luc],
we observed a strong
activation of luciferase activity not only
with vectors expressing
c-
fos and c-
jun genes (Fig.
4B, lane 6)
but also
with those expressing v-
rel and to a lesser extent
c-
rel (lanes 2 and 3). This strong activation by
v-
rel (a 35.8-fold
increase) was inhibited by cotransfection
with sup
jun-1 (lane
5). The activation of the
(AP-1)
5SV40-luc construct was AP-1 mediated,
since the
SV40-luc construct lacking AP-1-binding sites was not
activated by any
of the genes examined (lanes 8 to 12). Figure
4 shows the results
obtained from at least three different experiments.
The much stronger
activation of the (AP-1)
5SV40-luc construct
than of the
collagenase-CAT reporter was probably due to the presence
of multiple
AP-1-binding sites in the former construct instead
of just a single
AP-1 site in the latter construct. Furthermore,
the luciferase assay
system is more sensitive than the CAT assay
system. The results
obtained from these transactivation experiments
confirm that the
sup
jun-1 mutant can inhibit c-
jun- and
v-
rel-induced
transactivation of AP-1-controlled promoters
in CEFs.
AP-1 reporters are activated in Rel-transformed cells.
In the
previous section, it was demonstrated that Rel proteins increase the
expression of AP-1 reporter constructs in transient-transfection assays
(Fig. 4A and B). Next, we wanted to assay the expression of AP-1
reporter constructs in transformed cells. CEF cultures were infected
with control virus carrying no insert, DS3, v-rel, or
c-rel
. At 8 to 14 days later, when
rel-infected cells exhibited all features of morphological
transformation, the cells were transfected with
73/+63coll CAT or
(AP-1)5SV40-luc reporters. The transfection efficiency was
monitored by the expression of a cotransfected RSV
-Gal reporter. The
expression of both AP-1 reporter constructs was elevated in
Rel-transformed cells compared to that in uninfected CEF cultures or
those infected with control virus carrying no insert (DS3) (Fig.
5A and B). A more pronounced activation
of the AP-1 reporter constructs was detected in v-Rel-transformed cells
than in c-Rel
-transformed cells. The expression of Rel proteins had
no significant impact on the expression of reporter constructs lacking
AP-1 sites (
60/+63coll CAT, SV40-luc), indicating that the specific
activation of these constructs in the Rel-transformed cells was
mediated by AP-1 sites (Fig. 5). The activation of the
73/+63coll CAT
reporter construct in these experiments, as opposed to the
transient-transfection assays described in the previous section, is
probably due to the higher expression of Rel proteins in transformed
cells. The results of these experiments confirm that AP-1 activity is
significantly elevated in Rel-transformed cells.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 5.
(A) Activation of the collagenase promoter in
Rel-transformed CEF cultures. Transactivation was assayed by measuring
CAT activity in extracts of v-Rel- or c-Rel -transformed CEF cultures
transfected with the 73/+63coll CAT reporter gene (lanes 1 to 4, solid bars) or 60/+63coll CAT with the AP-1 sites deleted (lanes 5 to
8, empty bars) 24 h posttransfection. Lanes: 1 and 5, uninfected
CEF cultures; 2 and 6, DS3-infected CEF cultures; 3 and 7, c-Rel -transformed CEF cultures; 4 and 8, v-Rel-transformed CEF
cultures. (B) Activation of (AP-1)5SV40-luc in
Rel-transformed CEF cultures. Lanes: 1 and 5, uninfected CEF cultures;
2 and 6, DS3-infected CEF cultures; 3 and 7, c-Rel -transformed CEF
cultures; 4 and 8, v-Rel-transformed CEF cultures. Luciferase activity
for equal amounts of protein was determined as described in Materials
and Methods 36 h after transfection (65). Fold
activation was determined by dividing the actual chloramphenicol or
luciferase activity obtained from v-Rel- or c-Rel -transformed CEF
cultures by the activity of the reporter from normal CEF cultures or
those infected with an "empty" expression vector, DS3 (defined as
baseline activity 1.0). The mean results from two experiments with
standard errors are shown.
|
|
SupJun interferes with AP-1 DNA binding.
To determine if
supJun could affect wild-type c-Jun and c-Fos DNA binding, we tested
the ability of c-Jun and c-Fos to bind DNA containing an AP-1 site in
the presence and/or absence of the supJun protein. Proteins were
synthesized separately by using a reticulocyte lysate-based in vitro
transcription-translation system and then mixed and incubated at 37°C
for 45 min to allow the formation of dimers. The preincubated protein
mixture was then tested for DNA binding by an EMSA. The binding
reactions and electrophoresis were done at 4°C to detect the binding
of not only heterodimers but also the less stable homodimers. Figure 6A shows the results of one such assay.
The addition of c-Jun, c-Fos, or supJun alone to the
labeled AP-1 oligonucleotide resulted in the retardation of a specific
band corresponding to c-Jun/c-Jun homodimers (lane 2, band 1) and
supJun/supJun homodimers (lane 4, band 5) bound to DNA. These complexes
are AP-1 specific, since incubation with an unlabeled AP-1
oligonucleotide abolished their binding (lanes 3, 5, and 11). The major
complex migrating in the middle of the gel (labeled e) probably
represents endogenous AP-1-like activity in the reticulocyte lysate
(lane 1), since it was competed with an excess of unlabeled AP-1
oligonucleotide (lanes 3, 5, and 11). c-Fos alone was unable to bind
DNA (lane 6). The addition of c-Jun and c-Fos, supJun and c-Jun, or
supJun and c-Fos to the labeled AP-1 oligonucleotide resulted in the
retardation of specific complexes corresponding to c-Jun/c-Fos
heterodimers (lane 7, band 2), supJun/c-Jun heterodimers (lane 8, band
3), and supJun/c-Fos heterodimers (lane 9, band 4) bound to DNA. As
seen in lanes 8 and 9, the supJun protein competed with c-Jun and c-Fos
for binding to DNA on AP-1 sites either as supJun homodimers or as
c-Jun/supJun or c-Fos/supJun heterodimers. In addition, when c-Jun,
c-Fos, and supJun were mixed, supJun/c-Fos heterodimers represent the major DNA-binding complex, and this preferred dimerization decreased both c-Jun/c-Fos heterodimer formation and DNA binding (lane 10). Therefore, the supJun protein can form dimers with itself or with c-Jun
or c-Fos, and the resulting complexes can competitively inhibit
wild-type c-Jun or c-Fos from binding to AP-1 sites.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 6.
(A) DNA-binding activity of in vitro-translated c-Jun,
c-Fos, and supJun. Proteins were synthesized separately by using a
reticulocyte lysate-based in vitro transcription-translation system and
then mixed and incubated at 37°C for 45 min to allow dimerization.
The DNA-binding activity was determined by an EMSA with 1 ng of a
32P-labeled oligonucleotide containing the AP-1-binding
site (FSE2) and 4.5 µl of reticulocyte lysate mixture in the presence
(+) (lanes 3, 5, and 11) or absence ( ) (lanes 2, 4, and 6 to 10) of a
100-fold molar excess of unlabeled oligonucleotide. The positions of
the shifted c-Jun-, c-Fos-, and supJun homo- and heterodimer-containing
complexes are indicated by the numbers 1 to 5 (1, c-Jun/c-Jun; 2, c-Jun/c-Fos; 3, supJun/c-Jun; 4, supJun/c-Fos; 5, supJun/supJun). The
complex labeled e is due to the reticulocyte lysate since it was seen
when unprogrammed lysate was mixed with the oligonucleotide (lane 1).
(B) Complex formation between oligonucleotides containing consensus
AP-1 or mutant AP-1 sequences and nuclear proteins from CEF cultures.
Nuclear extracts (5 µg) from CEF cultures infected with viruses carrying no insert (DS3) (lanes 1 and 4),
v-rel (lanes 2 and 5), or c-rel (lane 3 and 6)
were assayed 10 days after infection for AP-1-binding activity with 0.2 ng of a 32P-labeled AP-1 oligonucleotide (lanes 1 to 3) or
mutant AP-1 oligonucleotide (lanes 4 to 6) (Santa Cruz). Bands A and B
represent AP-1 DNA-binding activity in DS3- and Rel-infected CEF
cultures, respectively. (C) Endogenous AP-1 DNA-binding activity in
nuclear extracts from infected CEF cultures and lymphoid cells. Nuclear
extracts (5 µg) from CEF cultures infected with viruses carrying no
insert (DS3) (lanes 1 and 14), v-rel (lanes 2, 6, 8, and
15), c-rel (lane 3), or supjun-1 (lanes 4, 7, 16, and 18) or coinfected with v-rel and supjun-1
(v + sj) (lanes 5 and 17) were assayed 10 days after infection for
AP-1-binding activity with 0.2 ng of a 32P-labeled AP-1
oligonucleotide (Santa Cruz). Lanes 1 to 8 and 14 to 18 show binding
activity in nuclear extracts isolated from CEF cultures, whereas lanes
9 to 13 show activity originating from v-Rel-transformed C4-1 lymphoid
cells superinfected with DS3 (lanes 9 and 12) or supjun-1
(lanes 10, 11, and 13) viruses (2.5 µg per lane). The specificity of
AP-1 binding was determined by competition assays with a 100-fold molar
excess of unlabeled oligonucleotide (+) or mutant oligonucleotide (m).
The top bands, A and B (lane 8), are most probably formed by dimers of
the Fos/Jun family. The lower bands, C and D, were detected in nuclear
extracts from supJun-expressing cells (lanes 4, 5, and 10) and
represent supJun heterodimers with Fos/Jun proteins and supJun
homodimers, respectively.
|
|
To compare protein complexes formed by in vitro-translated c-Fos,
c-Jun, and supJun with complexes formed with nuclear extracts
from
sup
jun-1-expressing CEF cultures, proteins in nuclear
extracts
were electrophoresed on the same gel adjacent to the in
vitro-translated
proteins (Fig.
6A, lane 12). A similar profile of
protein complexes
was observed between the in vitro-translated and the
nuclear extract
samples. The slower migration of the in
vitro-translated proteins
is most probably due to differences in
posttranslational modifications.
Next we examined the AP-1 DNA-binding activity in nuclear extracts
derived from CEF cultures infected with viruses containing
no insert,
expressing v-Rel, or expressing c-Rel

(Fig.
6B). Nuclear
extracts
prepared from CEF cultures infected with DS3 generated
two complexes (A
and B), of which the top band (A) represents
the major complex. Nuclear
extracts from CEF cultures expressing
v-Rel or c-Rel

demonstrated
greatly enhanced bandshifts (2.5-
to 3-fold increase) with the same
mobility observed in DS3-infected
CEF cultures (compare lane 2 with
lanes 3 and 4). These complexes
do not bind to a mutant AP-1
oligonucleotide (lanes 6 to 8). In
addition, competition experiments
were performed with a consensus
AP-1 or mutated AP-1 oligonucleotide as
the competitor (Fig.
6C).
In the presence of the mutated AP-1
oligonucleotide, the top bands
(A and B) were clearly visible, even at
a 100-fold molar excess
(lane 8). In contrast, a 100-fold excess of the
consensus AP-1
oligonucleotide completely abolished all complexes
(lanes 6, 7,
and 11). The slower-migrating complex (A) appears to
contain c-Jun
since it was sensitive to treatment with c-Jun antisera
(Fig.
6C, lanes 1 and 14). Unfortunately, we were unable to identify
any other AP-1 members in these complexes, since antiserum against
chicken c-Fos is not available and none of the purchased cross-reactive
Fra-2 antisera were able to supershift or inhibit specific protein-DNA
complexes (data not shown). The treatment of extracts from
v-Rel-transformed
cells with anti-c-Jun serum resulted in a significant
reduction
of AP-1-binding activity and the formation of two
supershifted
DNA-protein complexes (lane 15). To determine the binding
profile
of supJun in vivo and whether it functions by interfering with
the ability of endogenous AP-1 factors to bind to DNA, nuclear
extracts
from sup
jun-1-infected cells were examined. These extracts
generated additional complexes, as shown in lanes 4, 5 and 10.
Complexes designated C were detected mainly in nuclear extracts
derived
from CEFs (lanes 4 and 5). They most probably represent
supJun
heterodimers with Fos/Jun partners. Nuclear extracts from
lymphoid
cells (C4-1) superinfected with viruses expressing sup
jun-1
generated two additional fast-migrating bands (designated D [lane
10]) which correspond to supJun homodimers. It is not clear if
these
two bands represent different modifications of supJun dimers,
but both
forms supershifted upon addition of a panspecific Jun
antiserum (lane
13). The observed differences in the nature of
the supJun complexes in
CEFs and lymphoid cells may be related
to the level of supJun
expression as well as to the differences
in the level of AP-1 factors
expressed in these two cell systems.
Extracts from CEF cultures
coinfected with v-
rel- and sup
jun-1-expressing
viruses consistently generated lower levels of the
higher-molecular-weight
complexes (designated A and B) when compared to
CEF cultures infected
with v-
rel alone (compare lanes 2 and
5). This indicates that
supJun, by forming heterodimers with Fos/Jun
family members, competitively
inhibits these factors from binding to
AP-1 sites. In conclusion,
v-Rel-overexpressing cells exhibited
elevated levels of c-Jun
as well as elevated levels of AP-1-binding
activity. Moreover,
the expression of the supJun transdominant mutant
decreased AP-1-binding
activity, probably by modulating
c-
jun expression (as shown in
the previous section) and also
by competing with wild-type Fos/Jun
family members for binding to AP-1
sites.
SupJun inhibits v-Rel- and c-Rel
-induced transformation.
Consistent with the results of others, our data demonstrate that supJun
can function as a general inhibitor of AP-1 activity, as measured
through DNA-binding and transactivation assays (70). Since
elevated AP-1 activity in v-Rel-transformed cells indicates a possible
involvement of these early response genes in the v-Rel-induced transformation process, the effect of supJun on v-Rel transformation was examined. To perform these studies, CEF cultures were infected with
v-rel- and supjun-1-expressing viruses to
determine if supJun could block the transformation of this cell type.
Since transformed cells are known to display anchorage-independent
growth, transformation efficiency was assayed by growth in agar
suspension. Secondary cultures of CEFs were coinfected or sequentially
infected with viruses carrying the rel oncogenes and
supjun-1. Four days after the second infection, the cells
were plated in soft agar and the expression of the oncoproteins (v-Rel
or c-Rel
) and supJun was confirmed by Western blot analysis as
described in Materials and Methods (data not shown). No difference in
the expression of v-Rel or c-Rel
was observed in cells expressing
supJun from that in cells expressing these oncoproteins alone (data not
shown). While infection of CEF cultures with the DS3 vector alone
failed to transform CEFs, the v-Rel- or c-Rel
-containing viruses
produced multiple colonies in soft agar. On average, 105
v-rel-infected CEFs seeded in soft agar produced 229 colonies and 105 c-rel
-infected CEFs produced
201 colonies. The total numbers of colonies varied to some extent from
experiment to experiment but were not substantially reduced if
v-rel infection was followed by superinfection with DS3 of a
different subgroup (B) or if sequential infection was done in the
reverse order. However, coinfection of v-rel with
supjun-1 or infection of v-rel followed by
supjun-1 superinfection (or vice versa) demonstrated a
substantial inhibitory effect on colony formation in soft agar (Table
1). A similar suppressive effect of
supJun was detected in c-Rel
transformation (Table 1). The
suppressive effect of supJun expression on colony formation was
measured by determining the relative transformation efficiency, which
represents the transformation efficiency of Rel- and DS3-infected CEFs
(defined as 100%). The results show that transformation induced by
rel was efficiently suppressed by infection with
supjun-1 when evaluated by colony-forming activity (Table
1).
In addition, the suppressive effect of supJun was observed in the
cellular morphology (Fig.
7). When
DS3-infected CEF cultures
were subsequently infected with
v-
rel or c-
rel
, the cells were
clearly
morphologically transformed, assuming a polygonal cellular
morphology
with a high saturation density (compare Fig.
7A with
Fig.
7B and E). In
contrast, CEF cultures infected with sup
jun-1
followed by
v-
rel or c-
rel
retained a morphology similar
to that
of cells infected with the vector alone (compare Fig.
7A with
Fig.
7C and G). When the order of introduction of the
rel
genes
and sup
jun-1 was reversed, the inhibitory effect of
supJun on
Rel transformation was not substantially changed (Fig.
7D and
H).

View larger version (139K):
[in this window]
[in a new window]
|
FIG. 7.
Cellular morphology of sequentially infected CEF
cultures. CEF cultures were infected with the virus from subgroup A
first and superinfected 4 days later with the virus from subgroup B to
deliver the second gene. (A) CEF cultures infected with the virus
carrying no insert, DS3. (B and C) CEF cultures infected first with
c-rel followed by DS3 (B) or supjun-1 (C). (F
and G) CEF cultures infected first with v-rel followed by
DS3 (F) or supjun-1 (G). When the order of introduction of
the rel genes and supjun-1 or DS3 was reversed,
the inhibitory effect of supJun expression on the Rel-induced
transformation was not substantially changed: DS3 followed by
v-rel resulted in a transformed phenotype (E), whereas
infection of CEF cultures with the supjun-1 rendered them
resistant to subsequent transformation by v-Rel (H) or c-Rel (D).
Infected cells were passaged in vitro for 10 days after the second
superinfection and then photographed at a magnification of ×200.
|
|
Since the natural targets of the v-
rel oncogene are lymphoid
cells, we also examined whether supJun can inhibit or reduce
the
colony-forming activity of v-
rel-transformed lymphoid cells.
Two lymphoid cell lines which were derived from REV-T-infected
spleen
cells were used in this study (C4-1 and 160/2 represent
B and T cells,
respectively). All cell lines examined expressed
a high level of the
v-Rel oncoprotein (data not shown). For the
introduction of
sup
jun, a highly concentrated virus stock was
used and the
efficiency of virus infection was determined by indirect
immunofluorescence with a primary antibody to the
p19
gag protein. Seven days after infection, the
majority of the cells
(60 to 98%) showed strong expression of the gag
protein whereas
uninfected cells were completely negative. The
expression of supJun
was verified by Western blot analysis and is shown
in Fig.
3C.
The sup
jun-1 viral infection did not seem to
impair the growth
potential of the tested lymphoid cells when they were
grown in
mass culture at high density. However, when cells
superinfected
with sup
jun-1 were seeded in soft agar, a
dramatic decrease in
the number and size of colonies was observed
compared to those
for cells infected with control virus (DS3) (Table
1). Compared
to control cells, the sup
jun-1-superinfected
lymphoid cells fail
to grow when plated out in a limiting-dilution
assay (data not
shown). The in vivo function of supJun in CEFs and
lymphoid cells
was clearly dependent on its level of expression. When a
high
level of expression was reached, a more pronounced inhibitory
effect on soft agar colony formation was consistently observed.
In
conclusion, the results obtained from both CEF cultures and
v-Rel-transformed lymphoid cells consistently demonstrated that
the
transdominant mutant supJun, through its inhibition of AP-1
activity,
can also inhibit the oncogenic potential of v-Rel-transformed
cells.
This implies a direct involvement of AP-1 factors in the
v-Rel
transformation pathway.
 |
DISCUSSION |
The exact mechanisms by which oncogenes regulate the activity of
their "downstream targets" are still not understood. One of the
models developed to explain the mechanism by which v-Rel effects
transformation of avian lymphoid cells is that v-Rel binds to DNA and
directly alters the expression of cellular genes (30). The
role that v-Rel plays in gene expression has been controversial. Some
studies suggest that v-Rel may act as a dominant negative repressor of
B-dependent transcription (5, 40, 54, 62). The repressive
function, however, is not sufficient for transformation by v-Rel. A
C-terminal deletion mutant of v-Rel fully represses
B site-dependent
transcription but fails to transform cells (64, 77). v-Rel
also functions as a transcriptional activator. A few cellular genes are
activated by v-Rel more efficiently than by c-Rel, and these genes
might play an important role in v-Rel-induced transformation (10,
22, 37, 68, 76).
In this paper, we provide conclusive evidence that AP-1 factors are
directly involved in the v-Rel transformation pathway. supJun functions
as a general inhibitor of AP-1 activity in avian fibroblast and
lymphoid cells. Coinfection or sequential infection with viruses
expressing the v-rel oncogene and supjun-1
significantly reduces the ability of lymphoid cells to form colonies in
soft agar and interferes with the ability of v-Rel to morphologically transform avian fibroblasts (Table 1; Fig. 7). Fibroblast cultures transformed by v-Rel revert to a normal phenotype after infection by a
retroviral vector encoding supjun-1 (Fig. 7).
The major components of AP-1, c-Fos and c-Jun, belong to the family of
the immediate-early genes whose transcription is highly, rapidly, and
transiently activated upon stimulation by external stimuli (4,
47). c-Fos and c-Jun have been proposed to act as nuclear
third-messenger molecules that function in coupling short-term signals
to long-term adaptive changes in cell phenotype by regulating the
expression of specific target genes. Moreover, c-Fos and c-Jun are
metabolically unstable, being degraded rapidly with half-lives of about
10 and 60 min, respectively (47, 75). The instabilities of
these proteins are presumably important for down regulation of the
transactivation of target genes by AP-1, which appears to be essential
for regulating cellular function or normal cell cycle progression. When
continuously expressed at high levels, c-fos and
c-jun transform cells (14, 55). Our results
demonstrate that v-Rel induces the expression of c-fos and
c-jun, suppresses fra-2 expression, and has no
effect on junD expression. It is, however, unclear whether
the elevated expression is due to increased mRNA stability or increased
mRNA transcription. Other Rel proteins (c-Rel and c-Rel
) in addition
to v-Rel were evaluated for their regulatory effect on AP-1 components.
The transforming ability of Rel proteins correlated with their ability to alter the expression of AP-1 factors. Moreover, our results indicate
that the modulations of the expression of c-fos,
c-jun, and fra-2 by v-Rel are not transient. The
sustained elevated levels of c-fos and c-jun mRNA
and protein as well as suppressed levels of fra-2 were
observed at a number of time points in cells expressing v-Rel. It is
assumed that the prolonged induction or repression of these AP-1
components results in long-term changes in the composition of AP-1
complexes. Because different members of the fos and
jun families have distinct transcriptional activities and
possibly sequence recognition properties, changes in the composition of the AP-1 complex are likely to affect the level and spectrum of genes
under their control.
A strong differential effect of v-Rel on the expression of specific
AP-1 members suggests that v-Rel is highly selective in the activation
or repression of genes even within one family of transcription factors.
However, the mechanism by which v-Rel modulates the transcription of
different AP-1 members is not understood. Recently, it has been shown
that v-Rel activates the promoter of c-jun. Two regions in
the promoter are required: a
B site located between
87 and
76
and a region between
52 and +148 (22). Whether the
expression of c-fos and fra-2 is regulated directly by activating or repressing promoters through specific sequences or by an indirect mechanism remains to be determined. Generally, changes in AP-1 activity in response to extracellular signals are regulated both at the level of transcription of the fos and jun genes and by posttranslational
modifications of preexisting AP-1 factors (reviewed in references
31, 39, and 43). The observed
elevated levels of c-fos and c-jun mRNA in
v-Rel-transformed cells resulted in the increased synthesis of Fos-Jun
dimers and increased AP-1 activity (Fig. 1, 2, and 6B). This increased
AP-1 activity might further induce c-jun transcription
through the AP-1 motif, known as the TPA response element, in its
promoter (positive autoregulation). However, the expression of the
transdominant mutant supJun in CEF cultures leads to a decreased
expression of endogenous c-jun at both mRNA and protein
levels (Fig. 3). It is most likely that supJun/c-Jun heterodimers, due
to the absence of a transactivation domain in supJun, mediate less
efficient autoregulation of the c-jun promoter, leading to a
decreased expression of c-jun (quenching mechanism)
(12). It would be interesting to determine the effect of
supjun-1 on the expression of endogenous c-fos,
but such an analysis is not feasible due to the barely detectable
c-fos levels in exponentially growing cells. However, for
fra-2, whose basal expression may be determined, similar
experiments indicate that the level of Fra-2 and the extent of Fra-2
hyperphosphorylation were not affected by the expression of supJun
(70).
The induction of transcription from the c-fos promoter is an
early and complex event. Several cis elements mediate
c-fos induction to a diverse spectrum of extracellular
stimuli (15, 25, 36, 43, 73, 74). This results in increased
synthesis of c-Fos, which, upon translocation to the nucleus, combines
with preexisting Jun proteins to form AP-1 dimers that are more stable
than those formed by the Jun protein alone. However, the induction of
c-fos transcription is a transient event because of its
rapid repression by its own gene product (negative autoregulation)
(13, 46, 67, 79, 82). Decreased levels of Fos, in turn,
reduce both AP-1 activity and c-jun transcription
(31). The complex control of the fos promoter
presumably allows tight regulation of fos transcription
under different physiological conditions and in different cellular
environments (31). In contrast, our results clearly show
that v-Rel overexpression is accompanied by sustained elevated levels
of c-fos mRNA and probably c-Fos protein (Fig. 1D). v-Rel,
by an as yet unknown mechanism, interferes with the c-fos
negative autoregulatory circuit leading to long-term c-fos upregulation. Deregulated expression of c-Jun and c-Fos, in turn, might
lead to cell transformation. Therefore, it is likely that AP-1
components or at least their subsets are common target molecules which
are regulated by the
B pathway and mediate abnormal cell proliferation. Interestingly, other oncogenes have also been shown to
modulate AP-1 activity (4, 31, 70). In cells transformed by
v-src, c-Ha-ras, and N-terminally truncated
c-raf, the elevated levels of c-Jun and Fra-2 were observed
while c-Fos was not detectable. Since our results show a different
modulation pattern of the AP-1 family members, it is obvious that
different oncogenes use different mechanisms to alter AP-1 activity.
These may include, besides alterations in the expression of various
jun and fos genes, posttranslational modifications of preexisting and newly synthesized AP-1 complexes. The
activity of the AP-1 transcription factor is regulated by phosphorylation (reviewed in references 39 and
43). Phosphorylation by protein kinases can affect
the interaction of the transcription factor transactivation domain with
the transcriptional machinery (39). Further studies are
needed to determine if the expression of v-Rel alters the
phosphorylation status of different AP-1 factors, which might represent
another important mechanism mediating v-Rel-induced transformation.
 |
ACKNOWLEDGMENTS |
We thank H. Iba for providing the pREP(A), pREP(B), pDS3,
pfraRPA, and psupjun-1 plasmids and P. Vogt for providing
avian c-jun cDNA, c-Jun antisera (USC-3, USC-4), and
reporter plasmids
73/+63coll CAT and
60/+63coll CAT. In addition we
are grateful to R. Hrdlickova for providing the lymphoid cell line DT95
and the v-Rel-transformed lymphoid cell line 160/2.
This work was supported by National Institutes of Health grant CA
33192, the National Cancer Institute, and the Texas Advanced Research
Program. Part of this work was supported by a grant from the Academy of
Sciences of the Czech Republic (A5052503) to J.K.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, University of Texas at Austin, Austin, TX 78712-1095. Phone: (512) 471-5525. Fax: (512) 471-7088. E-mail:
bose{at}mail.utexas.edu.
 |
REFERENCES |
| 1.
|
Angel, P.,
I. Baumann,
B. Stein,
H. Delius,
H. J. Rahmsdorf, and P. Herrlich.
1987.
12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5'-flanking region.
Mol. Cell. Biol.
7:2256-2266[Abstract/Free Full Text].
|
| 2.
|
Angel, P.,
K. Hattori,
T. Smeal, and M. Karin.
1988.
The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1.
Cell
55:875-885[Medline].
|
| 3.
|
Angel, P.,
M. Imagawa,
R. Chiu,
B. Stein,
R. J. Imbra,
H. J. Rahmsdorf,
C. Jonat,
P. Herrlich, and M. Karin.
1987.
Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor.
Cell
49:729-739[Medline].
|
| 4.
|
Angel, P., and M. Karin.
1991.
The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation.
Biochim. Biophys. Acta
1072:129-157[Medline].
|
| 5.
|
Ballard, D. W.,
W. H. Walker,
S. Doerre,
P. Sista,
J. A. Molitor,
E. P. Dixon,
N. J. Peffer,
M. Hannink, and W. C. Greene.
1990.
The v-rel oncogene encodes a B enhancer binding protein that inhibits NF- B function.
Cell
63:803-814[Medline].
|
| 6.
|
Beg, A. A., and A. S. Baldwin, Jr.
1993.
The I B proteins: multifunctional regulators of Rel/NF- B transcription factors.
Genes Dev.
7:2064-2070[Free Full Text].
|
| 7.
|
Beug, H.,
H. Müller,
S. Grieser,
G. Doederlein, and T. Graf.
1981.
Hematopoietic cells transformed in vitro by REV-T avian reticuloendotheliosis virus express characteristics of very immature lymphoid cells.
Virology
115:295-309[Medline].
|
| 8.
|
Blank, V.,
P. Kourilsky, and A. Israel.
1992.
NF- B and related proteins: Rel/dorsal homologies meet ankyrin-like repeats.
Trends Biochem. Sci.
17:135-140[Medline].
|
| 9.
|
Boehmelt, G.,
J. Madruga,
P. Dörfler,
K. Briegel,
H. Schwartz,
P. J. Enrietto, and M. Zenke.
1995.
Dendritic cell progenitor is transformed by a conditional v-Rel estrogen receptor fusion protein v-RelER.
Cell
80:341-352[Medline].
|
| 10.
|
Boehmelt, G.,
A. Walker,
N. Kabrun,
G. Mellitzer,
H. Beug,
M. Zenke, and P. J. Enrietto.
1992.
Hormone-regulated v-rel estrogen receptor fusion protein: reversible induction of cell transformation and cellular gene expression.
EMBO J.
11:4641-4652[Medline].
|
| 11.
|
Bose, H. R., Jr.
1992.
The Rel family: models for transcriptional regulation and oncogenic transformation.
Biochim. Biophys. Acta
114:1-17.
|
| 12.
|
Brown, P. H.,
R. Alani,
L. H. Preis,
E. Szabo, and M. J. Birrer.
1993.
Suppression of oncogene-induced transformation by a deletion mutant of c-jun.
Oncogene
8:877-886[Medline].
|
| 13.
|
Cahill, M. A.
1997.
c-Fos transrepression revisited.
FEBS Lett.
400:9-10[Medline].
|
| 14.
|
Castellazzi, M.,
J.-P. Dangy,
F. Mechta,
S.-I. Hirai,
M. Yaniv,
J. Samarut,
A. Lassailly, and G. Brun.
1990.
Overexpression of avian or mouse c-jun in primary chick embryo fibroblasts confers a partially transformed phenotype.
Oncogene
5:1541-1547[Medline].
|
| 15.
|
Cavigelli, M.,
F. Dolfi,
F.-X. Claret, and M. Karin.
1995.
Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation.
EMBO J.
14:5957-5964[Medline].
|
| 16.
|
Chen, C., and H. Okayama.
1987.
High-efficiency transformation of mammalian cells by plasmid DNA.
Mol. Cell. Biol.
7:2745-2752[Abstract/Free Full Text].
|
| 17.
|
Cheng, Q.,
C. A. Cant,
T. Moll,
R. Hofer-Warbinek,
E. Wagner,
M. L. Birnstiel,
F. H. Bach, and R. de Martin.
1994.
NF- B subunit specific regulation of the I B promoter.
J. Biol. Chem.
269:13551-13557[Abstract/Free Full Text].
|
| 18.
|
Chiao, P. J.,
S. Miyamoto, and I. M. Verma.
1994.
Autoregulation of I B activity.
Proc. Natl. Acad. Sci. USA
91:28-32[Abstract/Free Full Text].
|
| 19.
|
Chomczynski, P., and N. Sacchi.
1987.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:156-159[Medline].
|
| 20.
|
Diehl, J. A., and M. Hannink.
1993.
Heterologous C-terminal sequences disrupt transcriptional activation and oncogenesis by p 59v-rel.
J. Virol.
67:7161-7171[Abstract/Free Full Text].
|
| 21.
|
Franklin, R. B.,
C.-Y. Kang,
K. M.-M. Wan, and H. R. Bose, Jr.
1977.
Transformation of chick embryo fibroblasts by reticuloendotheliosis virus.
Virology
83:313-321[Medline].
|
| 22.
|
Fujii, M.,
T. Minamino,
M. Nomura,
K.-I. Miyamoto,
J. Tanaka, and M. Seiki.
1996.
Selective activation of the proto-oncogene c-jun promoter by the transforming protein v-Rel.
Oncogene
12:2193-2202[Medline].
|
| 23.
|
Fujiwara, K. T.,
K. Ashida,
H. Nishina,
H. Iba,
N. Miyajima,
M. Nishizawa, and S. Kawai.
1987.
The chicken c-fos gene: cloning and nucleotide sequence analysis.
J. Virol.
61:4012-4018[Abstract/Free Full Text].
|
| 24.
|
Ghosh, S.,
A. M. Gifford,
L. R. Riviere,
P. Tempst,
G. P. Nolan, and D. Baltimore.
1990.
Cloning of the p50 DNA binding subunit of NF- B: homology to rel and dorsal.
Cell
62:1019-1029[Medline].
|
| 25.
|
Gille, H.,
M. Kortenjann,
T. Strahl, and P. E. Shaw.
1996.
Phosphorylation-dependent formation of a quaternary complex at the c-fos SRE.
Mol. Cell. Biol.
16:1094-1102[Abstract].
|
| 26.
|
Gilmore, T. D.
1991.
Malignant transformation by mutant Rel proteins.
Trends Genet.
7:318-322[Medline].
|
| 27.
|
Gilmore, T. D.
1992.
Role of rel family genes in normal and malignant lymphoid cell growth.
Cancer Surv.
15:69-87[Medline].
|
| 28.
|
Gilmore, T. D., and P. J. Morin.
1993.
The I B proteins: members of a multifunctional family.
Trends Genet.
9:427-433[Medline].
|
| 29.
|
Gilmore, T. D., and H. M. Temin.
1988.
v-rel oncoproteins in the nucleus and in the cytoplasm transform chicken spleen cells.
J. Virol.
62:703-714[Abstract/Free Full Text].
|
| 30.
|
Gilmore, T. D.,
D. W. White,
S. Sarkar, and S. Sif.
1995.
Malignant transformation of cells by the v-Rel oncoprotein, p. 109-128.
In
G. M. Cooper, R. G. Temin, and B. Sugden (ed.), The DNA provirus: Howard Temin's scientific legacy. American Society for Microbiology, Washington, D.C.
|
| 31.
|
Gutman, A., and B. Wasylyk.
1991.
Nuclear targets for transcription regulation by oncogenes.
Trends Genet.
7:49-54[Medline].
|
| 32.
|
Hanning, M., and H. M. Temin.
1989.
Transactivation of gene expression by nuclear and cytoplasmic rel proteins.
Mol. Cell. Biol.
9:4323-4336[Abstract/Free Full Text].
|
| 33.
|
Hartl, M.,
J. T. Hutchins, and P. K. Vogt.
1991.
The chicken junD gene and its product.
Oncogene
6:1623-1631[Medline].
|
| 34.
|
Havarstein, L. S.,
I. M. Morgan,
W.-Y. Wong, and P. K. Vogt.
1992.
Mutations in the Jun Delta region suggest an inverse correlation between transformation and transcription activation.
Proc. Natl. Acad. Sci. USA
89:618-622[Abstract/Free Full Text].
|
| 35.
|
Henkel, T.,
U. Zabel,
K. van Zee,
J. M. Müller,
E. Fanning, and P. A. Baeuerle.
1992.
Intramolecular masking of the nuclear location signal and dimerization domain of the precursor for the p50 NF- B subunit.
Cell
68:1121-1133[Medline].
|
| 36.
|
Hill, C. S., and R. Treisman.
1995.
Differential activation of c-fos promoter elements by serum, lysophosphatidic acid, G proteins and polypeptide growth factors.
EMBO J.
14:5037-5047[Medline].
|
| 37.
|
Hrdlickova, R.,
J. Nehyba, and E. H. Humphries.
1994.
v-rel induces expression of three avian immunoregulatory surface receptors more efficiently than c-rel.
J. Virol.
68:308-319[Abstract/Free Full Text].
|
| 38.
|
Hrdlickova, R.,
J. Nehyba,
A. Roy,
E. H. Humphries, and H. R. Bose, Jr.
1995.
The relocalization of v-Rel from the nucleus to the cytoplasm coincides with induction of expression of Ikba and nfkb1 and stabilization of I B- .
J. Virol.
69:403-413[Abstract].
|
| 39.
|
Hunter, T., and M. Karin.
1992.
The regulation of transcription by phosphorylation.
Cell
70:375-387[Medline].
|
| 40.
|
Inoue, J.-I.,
L. D. Kerr,
L. J. Ransone,
E. Bengal,
T. Hunter, and I. M. Verma.
1991.
c-rel activates but v-rel suppresses transcription from B sites.
Proc. Natl. Acad. Sci. USA
88:3715-3719[Abstract/Free Full Text].
|
| 41.
|
Ito, C. Y.,
A. G. Kazantsev, and A. S. Baldwin, Jr.
1994.
Three NF- B sites in the I B promoter are required for induction of gene expression by TNF .
Nucleic Acids Res.
22:3787-3792[Abstract/Free Full Text].
|
| 42.
|
Kabrun, N.,
J. W. Hodgson,
M. Doemer,
G. Mak,
B. R. Franza, Jr., and P. J. Enrietto.
1991.
Interaction of the v-rel protein with an NF- B DNA binding site.
Proc. Natl. Acad. Sci. USA
88:1783-1787[Abstract/Free Full Text].
|
| 43.
|
Karin, M.
1995.
The regulation of AP-1 activity by mitogen-activated protein kinases.
J. Biol. Chem.
270:16483-16486[Free Full Text].
|
| 44.
|
Kerr, L. D.,
J.-I. Inoue,
N. Davis,
E. Link,
P. A. Baeuerle,
H. R. Bose, Jr., and I. M. Verma.
1991.
The Rel-associated pp40 protein prevents DNA binding of Rel and NF- B: relationship with I B and regulation by phosphorylation.
Genes Dev.
5:1464-1476[Abstract/Free Full Text].
|
| 45.
|
Kieran, M.,
V. Blank,
F. Logeat,
J. Vanderkerckhove,
F. Lottspeich,
O. Le Bail,
M. B. Urban,
P. Kourilsky,
P. A. Baeuerle, and A. Israel.
1990.
The DNA binding subunit of NF- B is identical to factor KBF1 and homologous to the rel oncogene product.
Cell
62:1007-1018[Medline].
|
| 46.
|
König, H.,
H. Ponta,
U. Rahmsdorf,
M. Büscher,
A. Schönthal,
H. J. Rahmsdorf, and P. Herrlich.
1989.
Autoregulation of fos: the dyad symmetry element as the major target of repression.
EMBO J.
8:2559-2566[Medline].
|
| 47.
|
Kovary, K., and R. Bravo.
1991.
Expression of different Jun and Fos proteins during the G0-to-G1 transition in mouse fibroblasts: in vitro and in vivo associations.
Mol. Cell. Biol.
11:2451-2459[Abstract/Free Full Text].
|
| 48.
|
Kralova, J.,
J. D. Schatzle,
W. Bargmann, and H. R. Bose, Jr.
1994.
Transformation of avian fibroblast overexpression of c-rel proto-oncogene and a variant of c-rel lacking 40 C-terminal amino acids.
J. Virol.
68:2073-2083[Abstract/Free Full Text].
|
| 49.
|
Kralova, J.,
J. D. Schatzle,
A. S. Liss,
W. Bargmann, and H. R. Bose, Jr.
1996.
Synergistic stimulation of avian I B transcription by rel and fos/jun factors.
Oncogene
12:2595-2604[Medline].
|
| 50.
|
Kumar, S.,
A. B. Rabson, and C. Gélinas.
1992.
The RxxRxRxxC motif conserved in all Rel/ B proteins is essential for the DNA binding activity and redox regulation of the v-Rel oncoprotein.
Mol. Cell. Biol.
12:3094-3106[Abstract/Free Full Text].
|
| 51.
|
Le Bail, O.,
R. Schmidt-Ullrich, and A. Israel.
1993.
Promoter analysis of the gene encoding the I B / MAD-3 inhibitor of NF- B: positive regulation by members of the rel/NF- B family.
EMBO J.
12:5043-5049[Medline].
|
| 52.
|
Lewis, R. B.,
J. McClure,
B. Rup,
D. W. Niesel,
R. F. Garry,
J. D. Hoelzer,
K. Nazerian, and H. R. Bose, Jr.
1981.
Avian reticuloendotheliosis virus: identification of the hematopoietic target cell for transformation.
Cell
25:421-431[Medline].
|
| 53.
|
Lim, M. Y.,
N. Davis,
J. Zhang, and H. R. Bose, Jr.
1990.
The v-rel oncogene product is complexed with the cellular proteins including its proto-oncogene product and heat shock protein 70.
Virology
175:149-160[Medline].
|
| 54.
|
McDonnel, P. C.,
S. Kumar,
A. B. Rabson, and C. Gélinas.
1992.
Transcriptional activity of rel family proteins.
Oncogene
7:163-170[Medline].
|
| 55.
|
Miller, A.,
T. Curran, and I. M. Verma.
1984.
c-fos protein can induce cellular transformation: a novel mechanism of activation of a cellular oncogene.
Cell
36:51-60[Medline].
|
| 56.
|
Moore, B. E., and H. R. Bose, Jr.
1988.
Expression of the v-rel oncogene in reticuloendotheliosis virus-transformed fibroblasts.
Virology
162:377-387[Medline].
|
| 57.
|
Morrison, L. E.,
G. Boehmelt,
H. Beug, and P. J. Enrietto.
1991.
Expression of v-rel in a replication competent virus: transformation and biochemical characterization.
Oncogene
6:1657-1666[Medline].
|
| 58.
|
Morrison, L. E.,
G. Boehmelt, and P. J. Enrietto.
1992.
Mutations in the rel-homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts.
Oncogene
7:1137-1147[Medline].
|
| 59.
|
Nishimura, T., and P. K. Vogt.
1988.
The avian cellular homolog of the oncogene jun.
Oncogene
3:659-663[Medline].
|
| 60.
|
Nishina, H.,
H. Sato,
T. Suzuki,
M. Sato, and H. Iba.
1990.
Isolation and characterization of fra-2, an additional member of the fos gene family.
Proc. Natl. Acad. Sci. USA
87:3619-3623[Abstract/Free Full Text].
|
| 61.
|
Okuno, H.,
T. Suzuki,
T. Yoshida,
Y. Hashimoto,
T. Curran, and H. Iba.
1991.
Inhibition of jun transformation by a mutated fos gene: design of an anti-oncogene.
Oncogene
6:1491-1497[Medline].
|
| 62.
|
Richardson, P. M., and T. G. Gilmore.
1991.
v-Rel is an inactive member of the Rel family of transcriptional activating proteins.
J. Virol.
65:3122-3130[Abstract/Free Full Text].
|
| 63.
|
Sambrook, J.,
F. F. Fritsch, and T. Maniatis.
1989.
In
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 64.
|
Sarkar, S., and T. D. Gilmore.
1993.
Transformation by the v-Rel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.
Oncogene
8:2245-2252[Medline].
|
| 65.
|
Schatzle, J. D.,
J. Kralova, and H. R. Bose, Jr.
1995.
Avian I B is transcriptionally induced by c-Rel and v-Rel with different kinetics.
J. Virol.
69:5383-5390[Abstract].
|
| 66.
|
Schreiber, S.,
P. Matthias,
M. M. Müller, and W. Schaffner.
1989.
Rapid detection of octamer binding proteins with `mini-extracts' prepared from a small number of cells.
Nucleic Acids Res.
17:6419[Free Full Text].
|
| 67.
|
Shaw, P. E.,
S. Frasch, and A. Nordheim.
1989.
Repression of c-fos transcription is mediated through p 67SRF bound to the SRE.
EMBO J.
8:2567-2574[Medline].
|
| 68.
|
Sif, S.,
A. J. Capobianco, and T. D. Gilmore.
1993.
The v-Rel oncoprotein increases expression from Sp1 site-containing promoters in chicken embryo fibroblasts.
Oncogene
8:2501-2509[Medline].
|
| 69.
|
Stephens, R. M.,
N. R. Rice,
R. R. Hiebsch,
H. R. Bose, Jr., and R. V. Gilden.
1983.
Nucleotide sequence of v-rel: the oncogene of reticuloendotheliosis virus.
Proc. Natl. Acad. Sci. USA
80:6229-6233[Abstract/Free Full Text].
|
| 70.
|
Suzuki, T.,
M. Murakami,
N. Onai,
E. Fukuda,
Y. Hashimoto,
M. H. Sonobe,
T. Kameda,
M. Ichinose,
K. Miki, and H. Iba.
1994.
Analysis of AP-1 function in cellular transformation pathways.
J. Virol.
68:3527-3535[Abstract/Free Full Text].
|
| 71.
|
Suzuki, T.,
H. Okuno,
T. Yoshida,
T. Endo,
H. Nishina, and H. Iba.
1991.
Difference in transcriptional regulatory function between c-Fos and Fra-2.
Nucleic Acids Res.
19:5537-5542[Abstract/Free Full Text].
|
| 72.
|
Traechner, E.B.-M.,
S. Wilk, and P. A. Baeuerle.
1994.
A proteasome inhibitor prevents activation of NF- B and stabilizes a newly phosphorylation form of I B that is still bound to NF- B.
EMBO J.
13:5433-5441[Medline].
|
| 73.
|
Treisman, R.
1992.
The serum response element.
Trends Biochem. Sci.
17:423-426[Medline].
|
| 74.
|
Treisman, R.
1994.
Ternary complex factors: growth factor regulated transcriptional activators.
Curr. Opin. Genet. Dev.
4:96-101[Medline].
|
| 75.
|
Tsurumi, C.,
N. Ishida,
T. Tamura,
A. Kakizuka,
E. Nishida,
E. Okumura,
T. Kishimoto,
M. Inakagi,
K. Okazaki,
N. Sagata,
A. Ichihara, and K. Tanaka.
1995.
Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases.
Mol. Cell. Biol.
15:5682-5687[Abstract].
|
| 76.
|
Walker, A. K., and P. J. Enrietto.
1996.
Analysis of the role of v-rel in transcriptional regulation of high mobility group protein 14.
Oncogene
12:2515-2525[Medline].
|
| 77.
|
Walker, W. H.,
B. Stein,
P. A. Ganchi,
J. A. Hoffman,
P. A. Kaufman,
D. W. Ballard,
M. Hannink, and W. C. Greene.
1992.
The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation.
J. Virol.
66:5018-5029[Abstract/Free Full Text].
|
| 78.
|
Wilhelmsen, K. C.,
K. Eggleton, and H. M. Temin.
1984.
Nucleic acid sequence of the oncogene v-rel in reticuloendotheliosis virus strain T and its cellular homolog, the proto-oncogene c-rel.
J. Virol.
52:172-182[Abstract/Free Full Text].
|
| 79.
|
Wilson, T., and R. Treisman.
1988.
Fos C-terminal mutations block down-regulation of c-fos transcription following serum stimulation.
EMBO J.
7:4193-4201[Medline].
|
| 80.
|
Zhang, J.,
W. Olson,
D. Ewert,
W. Bargmann, and H. R. Bose, Jr.
1991.
The v-rel oncogene of avian reticuloendotheliosis virus transforms immature and mature lymphoid cells in B cell lineage in vitro.
Virology
183:457-466[Medline].
|
| 81.
|
Zhang, J., and H. R. Bose, Jr.
1989.
Acquisition of new proviral copies in avian lymphoid cells transformed by reticuloendotheliosis virus.
J. Virol.
63:1107-1115[Abstract/Free Full Text].
|
| 82.
|
Zinck, R.,
R. A. Hipskind,
V. Pingoud, and A. Nordheim.
1993.
c-fos transcriptional activation and repression correlate temporally with the phosphorylation status of TCF.
EMBO J.
12:2377-2387[Medline].
|
Mol Cell Biol, May 1998, p. 2997-3009, Vol. 18, No. 5
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bolisetty, M. T., Dy, G., Tam, W., Beemon, K. L.
(2009). Reticuloendotheliosis Virus Strain T Induces miR-155, Which Targets JARID2 and Promotes Cell Survival. J. Virol.
83: 12009-12017
[Abstract]
[Full Text]
-
Schnidar, H., Eberl, M., Klingler, S., Mangelberger, D., Kasper, M., Hauser-Kronberger, C., Regl, G., Kroismayr, R., Moriggl, R., Sibilia, M., Aberger, F.
(2009). Epidermal Growth Factor Receptor Signaling Synergizes with Hedgehog/GLI in Oncogenic Transformation via Activation of the MEK/ERK/JUN Pathway. Cancer Res.
69: 1284-1292
[Abstract]
[Full Text]
-
Dutta, J., Fan, G., Gelinas, C.
(2008). CAPER{alpha} Is a Novel Rel-TAD-Interacting Factor That Inhibits Lymphocyte Transformation by the Potent Rel/NF-{kappa}B Oncoprotein v-Rel. J. Virol.
82: 10792-10802
[Abstract]
[Full Text]
-
Gupta, N., Delrow, J., Drawid, A., Sengupta, A. M., Fan, G., Gelinas, C.
(2008). Repression of B-Cell Linker (BLNK) and B-Cell Adaptor for Phosphoinositide 3-Kinase (BCAP) Is Important for Lymphocyte Transformation by Rel Proteins. Cancer Res.
68: 808-814
[Abstract]
[Full Text]
-
De Lorenzo, M. S., Yamaguchi, K., Subbaramaiah, K., Dannenberg, A. J.
(2003). Bryostatin-1 Stimulates the Transcription of Cyclooxygenase-2: Evidence for an Activator Protein-1-Dependent Mechanism. Clin. Cancer Res.
9: 5036-5043
[Abstract]
[Full Text]
-
Rayet, B., Fan, Y., Gelinas, C.
(2003). Mutations in the v-Rel Transactivation Domain Indicate Altered Phosphorylation and Identify a Subset of NF-{kappa}B-Regulated Cell Death Inhibitors Important for v-Rel Transforming Activity. Mol. Cell. Biol.
23: 1520-1533
[Abstract]
[Full Text]
-
Kralova, J., Liss, A. S., Bargmann, W., Pendleton, C., Varadarajan, J., Ulug, E., Bose, H. R. Jr.
(2002). Differential Regulation of the Inhibitor of Apoptosis ch-IAP1 by v-rel and the Proto-Oncogene c-rel. J. Virol.
76: 11960-11970
[Abstract]
[Full Text]
-
Nehyba, J., Hrdlickova, R., Burnside, J., Bose, H. R. Jr.
(2002). A Novel Interferon Regulatory Factor (IRF), IRF-10, Has a Unique Role in Immune Defense and Is Induced by the v-Rel Oncoprotein. Mol. Cell. Biol.
22: 3942-3957
[Abstract]
[Full Text]
-
Liss, A. S., Bose, H. R. Jr.
(2002). Mutational Analysis of the v-Rel Dimerization Interface Reveals a Critical Role for v-Rel Homodimers in Transformation. J. Virol.
76: 4928-4939
[Abstract]
[Full Text]
-
Espinosa, L., Santos, S., Ingles-Esteve, J., Munoz-Canoves, P., Bigas, A.
(2002). p65-NF{kappa}B synergizes with Notch to activate transcription by triggering cytoplasmic translocation of the nuclear receptor corepressor N-CoR. J. Cell Sci.
115: 1295-1303
[Abstract]
[Full Text]
-
Bose, H. R. Jr.
(2001). Interferon Regulatory Factor 4 Contributes to Transformation of v-Rel-Expressing Fibroblasts. Mol. Cell. Biol.
21: 6369-6386
[Abstract]
[Full Text]
-
Hennigan, R. F., Stambrook, P. J.
(2001). Dominant Negative c-jun Inhibits Activation of the Cyclin D1 and Cyclin E Kinase Complexes. Mol. Biol. Cell
12: 2352-2363
[Abstract]
[Full Text]
-
Yu, R., Hebbar, V., Kim, D. W., Mandlekar, S., Pezzuto, J. M., Kong, A.-N. T.
(2001). Resveratrol Inhibits Phorbol Ester and UV-Induced Activator Protein 1 Activation by Interfering with Mitogen-Activated Protein Kinase Pathways. Mol. Pharmacol.
60: 217-224
[Abstract]
[Full Text]
-
Chen, C., Agnes, F., Gelinas, C.
(1999). Mapping of a Serine-Rich Domain Essential for the Transcriptional, Antiapoptotic, and Transforming Activities of the v-Rel Oncoprotein. Mol. Cell. Biol.
19: 307-316
[Abstract]
[Full Text]
-
Malliri, A., Symons, M., Hennigan, R. F., Hurlstone, A. F.L., Lamb, R. F., Wheeler, T., Ozanne, B. W.
(1998). The Transcription Factor AP-1 Is Required for EGF-induced Activation of Rho-like GTPases, Cytoskeletal Rearrangements, Motility, and In Vitro Invasion of A431 Cells. JCB
143: 1087-1099
[Abstract]
[Full Text]